Medicaments for the Treatment or Prevention of Fibrotic Diseases
申请人:Park Edward John
公开号:US20060154939A1
公开(公告)日:2006-07-13
The present invention relates to the use of indolinones of general formula
substituted in the 6 position, wherein R
1
to R
5
and X are defined as in claim
1
, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
本发明涉及通式为
其中 R
1
至 R
5
和X的定义如权利要求
1
4.3.2 异构体及其盐类,特别是其生理上可接受的盐类,可作为预防或治疗特定纤维化疾病的药物。
MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
申请人:Boehringer Ingelheim International GmbH
公开号:EP1830842B1
公开(公告)日:2009-04-22
US6858641B2
申请人:——
公开号:US6858641B2
公开(公告)日:2005-02-22
Substituted indolinones
申请人:——
公开号:US20030092756A1
公开(公告)日:2003-05-15
The present invention relates to indolinones substituted in the 6-position of general formula
1
wherein
R
1
to R
5
and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.